Financial Survey: WuXi PharmaTech (Cayman) (WX) versus Sunesis Pharmaceuticals (SNSS)
WuXi PharmaTech (Cayman) (NYSE: WX) and Sunesis Pharmaceuticals (NASDAQ:SNSS) are both biotechnology & medical research – nec companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
This is a breakdown of current ratings for WuXi PharmaTech (Cayman) and Sunesis Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|WuXi PharmaTech (Cayman)||0||0||0||0||N/A|
Sunesis Pharmaceuticals has a consensus price target of $4.16, suggesting a potential downside of 2.12%. Given Sunesis Pharmaceuticals’ higher possible upside, analysts clearly believe Sunesis Pharmaceuticals is more favorable than WuXi PharmaTech (Cayman).
Earnings & Valuation
This table compares WuXi PharmaTech (Cayman) and Sunesis Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|WuXi PharmaTech (Cayman)||N/A||N/A||N/A||$1.18||38.91|
|Sunesis Pharmaceuticals||$2.54 million||57.31||-$38.02 million||($1.75)||-2.43|
WuXi PharmaTech (Cayman) has higher earnings, but lower revenue than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a lower price-to-earnings ratio than WuXi PharmaTech (Cayman), indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
38.2% of Sunesis Pharmaceuticals shares are held by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares WuXi PharmaTech (Cayman) and Sunesis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|WuXi PharmaTech (Cayman)||7.52%||6.93%||4.67%|
About WuXi PharmaTech (Cayman)
WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Receive News & Ratings for WuXi PharmaTech (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi PharmaTech (Cayman) and related companies with Analyst Ratings Network's FREE daily email newsletter.